Differential Changes in Platelet VEGF, Tsp, CXCL12, and CXCL4 in Patients with Metastatic Cancer

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2010 Feb 26

PMID 20182908

Citations 38

Authors

Tina Wiesner

Stefanie Bugl

Frank Mayer

Jorg T Hartmann

Hans-Georg Kopp

Affiliations

Soon will be listed here.

Abstract

Data from animal studies indicate that platelets play a key role in tumor dissemination and metastasis. We therefore hypothesized that metastastic cancer patients may display a specific platelet phenotype. Percentage of activated, p-selectin positive platelets as well as platelet contents (i.e., plasma and platelet count-corrected serum levels of VEGF-A, CXCL12, CXCL4, and thrombospondin-1) were analyzed in 43 patients with newly diagnosed metastatic disease prior to treatment. Tumor patients had increased platelet counts and significantly elevated percentages of activated platelets. Moreover, the platelet content of VEGF-A in cancer patients was significantly increased compared to healthy controls, while thrombospondin-1, CXCL12 and CXCL4 were significantly decreased. Our data contain several unexpected results: firstly, CXCL12 was found in minute quantities in the serum as compared with murine studies. Secondly, CXCL4, which was found by mass spectrometry to be the single massively upregulated intraplatelet chemokine in mice after tumor xenotransplantation, was decreased in tumor patient platelets. While increased contents of VEGF-A have been attributed to platelet scavenger activity, the differential decrease of specific platelet contents may be due to differential secretion or altered megakaryopoiesis in metastatic cancer patients.

Citing Articles

Blockade of TSP-1/CD47 signal axis promotes donor hematopoietic engraftment by improving SEC/MK niche function.

Wang F, Liu Y, Zhang T, Hou X, Xin Y, Xie G iScience. 2025; 28(3):111952.

PMID: 40060904 PMC: 11889568. DOI: 10.1016/j.isci.2025.111952.

Nanoscale insights into hematology: super-resolved imaging on blood cell structure, function, and pathology.

Liu J, Tan Y, Zheng W, Wang Y, Ju L, Su Q J Nanobiotechnology. 2024; 22(1):363.

PMID: 38910248 PMC: 11194919. DOI: 10.1186/s12951-024-02605-2.

Platelet-derived microvesicles isolated from type-2 diabetes mellitus patients harbour an altered miRNA signature and drive MDA-MB-231 triple-negative breast cancer cell invasion.

Tutuianu A, Anene C, Shelton M, Speirs V, Whitelaw D, Thorpe J PLoS One. 2024; 19(6):e0304870.

PMID: 38900754 PMC: 11189239. DOI: 10.1371/journal.pone.0304870.

The Naples Prognostic Score Is a Useful Tool to Assess Surgical Treatment in Non-Small Cell Lung Cancer.

Elia S, Patirelis A, Hardavella G, Santone A, Carlea F, Pompeo E Diagnostics (Basel). 2023; 13(24).

PMID: 38132225 PMC: 10742842. DOI: 10.3390/diagnostics13243641.

Heterodimers Are an Integral Component of Chemokine Signaling Repertoire.

Kaffashi K, Dreau D, Nesmelova I Int J Mol Sci. 2023; 24(14).

PMID: 37511398 PMC: 10380872. DOI: 10.3390/ijms241411639.

References

Baenziger N, Brodie G, MAJERUS P . A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci U S A. 1971; 68(1):240-3. PMC: 391203. DOI: 10.1073/pnas.68.1.240. View

Wynendaele W, Derua R, Hoylaerts M, Pawinski A, Waelkens E, de Bruijn E . Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?. Ann Oncol. 1999; 10(8):965-71. DOI: 10.1023/a:1008377921886. View

Cervi D, Yip T, Bhattacharya N, Podust V, Peterson J, Abou-Slaybi A . Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2007; 111(3):1201-7. DOI: 10.1182/blood-2007-04-084798. View

Nagasawa T . A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of hematopoiesis. Int J Hematol. 2001; 72(4):408-11. View

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

Borsig L . The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008; 8(8):1247-55. DOI: 10.1586/14737140.8.8.1247. View

Maione T, GRAY G, Petro J, Hunt A, Donner A, Bauer S . Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990; 247(4938):77-9. DOI: 10.1126/science.1688470. View

Borsig L, Wong R, Feramisco J, Nadeau D, Varki N, Varki A . Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001; 98(6):3352-7. PMC: 30657. DOI: 10.1073/pnas.061615598. View

Nachman R, Rafii S . Platelets, petechiae, and preservation of the vascular wall. N Engl J Med. 2008; 359(12):1261-70. PMC: 2935201. DOI: 10.1056/NEJMra0800887. View

10.

Palumbo J, Talmage K, Massari J, La Jeunesse C, Flick M, Kombrinck K . Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007; 110(1):133-41. PMC: 1896107. DOI: 10.1182/blood-2007-01-065995. View

11.

George M, Tutton M, Janssen F, Arnaout A, Abulafi A, Eccles S . VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001; 3(5):420-7. PMC: 1506210. DOI: 10.1038/sj.neo.7900186. View

12.

Kopp H, Placke T, Salih H . Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009; 69(19):7775-83. DOI: 10.1158/0008-5472.CAN-09-2123. View

13.

Jin D, Shido K, Kopp H, Petit I, Shmelkov S, Young L . Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med. 2006; 12(5):557-67. PMC: 2754288. DOI: 10.1038/nm1400. View

14.

Mohle R, Green D, Moore M, Nachman R, Rafii S . Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997; 94(2):663-8. PMC: 19570. DOI: 10.1073/pnas.94.2.663. View

15.

Folkman J, Shing Y . Angiogenesis. J Biol Chem. 1992; 267(16):10931-4. View

16.

Adams J, Lawler J . The thrombospondins. Int J Biochem Cell Biol. 2004; 36(6):961-8. PMC: 2885884. DOI: 10.1016/j.biocel.2004.01.004. View

17.

Kopp H, Hooper A, Broekman M, Avecilla S, Petit I, Luo M . Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest. 2006; 116(12):3277-91. PMC: 1679710. DOI: 10.1172/JCI29314. View

18.

Gastl G, Plante M, Finstad C, Wong G, Federici M, Bander N . High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol. 1993; 83(3):433-41. DOI: 10.1111/j.1365-2141.1993.tb04668.x. View

19.

Coppinger J, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond J . Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2003; 103(6):2096-104. DOI: 10.1182/blood-2003-08-2804. View

20.

Brill A, Elinav H, Varon D . Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res. 2004; 63(2):226-35. DOI: 10.1016/j.cardiores.2004.04.012. View